Serum periostin in obstructive airways disease.

Serum periostin is a potential biomarker of response to therapies that target type 2 inflammation in asthma. The objectives of this study were to describe: 1) the distribution of serum periostin levels in adults with symptomatic airflow obstruction; 2) its relationship with other variables, including type 2 biomarkers; and 3) the effect of inhaled corticosteroids on periostin levels.Serum periostin levels were measured in a cross-sectional study exploring phenotypes and biomarkers in 386 patients aged 18-75 years who reported wheeze and breathlessness in the past 12 months.

Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults.

Background: Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment.

Objective: The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy.

Methods: We undertook a cross-sectional study with 3 phases.

Hydrothermal upgrading of biomass to biofuel; studies on some monosaccharide model compounds.

During the hydrothermal upgrading of biomass, hydrolysis to glucose is an important step. To elucidate some of the reaction pathways that follow this initial hydrolysis, the hydrothermal treatment (340 degrees C, 27.5 MPa, 25-204 s) of dilute (50 mM) solutions of D-glucose and some other monosaccharides were studied.

Effect of sevoflurane on the ex vivo secretion of TNF-alpha during and after coronary artery bypass surgery.

Background And Objective: Sevoflurane has been used for the induction and maintenance of anaesthesia during cardiac surgery owing to its favourable haemodynamic effects. It has been suggested that it offers protection against myocardial ischaemia-reperfusion injury.

Methods: We investigated the effect of sevoflurane on plasma concentrations of tumour necrosis factor-alpha (TNF-alpha) after ex vivo stimulation of whole-blood leukocytes by lipopolysaccharide from 20 patients undergoing coronary artery bypass surgery.

Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?

In this article we report on a meta-analysis of the published studies of amisulpride conducted in order to demonstrate efficacy on primary negative symptoms in schizophrenia. Four placebo-controlled studies were conducted in patients with predominantly negative symptoms. In all studies a significant improvement was observed on the Scale for the Assessment of Negative Symptoms (SANS) in the amisulpride groups (50-300 mg daily) as compared to placebo.